Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Status:
Active, not recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well azacitidine and enasidenib work in
treating patients with IDH2-mutant myelodysplastic syndrome. Azacitidine and enasidenib may
stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.